Andrew Walters 3/22/12 Biopure Biopure Corporation specializes in blood substitutes for transfusion patients‚ both in the veterinary market and the human market. However‚ in 1998‚ Biopure faced the monumental decision of whether to begin selling Oxyglobin‚ a blood substitute‚ to the veterinary market or to wait until Hemoglobin‚ a blood substitute for the human market‚ became available for sale. The problem is whether or not the company should launch Oxyglobin before Hemoglobin is FDA-approved
Premium Blood transfusion Blood
I will examine the challenges faced by Biopure in sequencing the release of 2 drugs. One ‚Oxyglobin‚ is ready for the Veterinary Market‚ and the other‚ Hemopure‚ whose success could rely on the brand management of the former. I will look at issues related to the success of the company and make the recommendation to launch Oxyglobin now. Currently Biopure creates blood products for two markets‚ human and veterinary. While Oxyglobin is ready to release for the veterinary market‚ Hemopure is 2 years
Premium Blood Blood transfusion
INTRODUCTION In the case of Biopure‚ the issue is to decide whether to launch Oxyglobin and how to launch it without jeopardizing the potential of Hemopure. Oxyglobin is a substitute to animal blood while Hemopure is a substitute to human blood. The CEO need to identify the influence of the launch of Oxyglobin bring to Hemopure. If the company is launching Oxyglobin‚ the CEO need to decide the price‚ identify the target client‚ choose distributing method and consider the production capacity. The
Free Blood Blood transfusion Veterinary medicine
BIOPURE CASE SUMMARY Course: Strategic Marketing Management Name: Firat Sekerli The Problem: Biopure Corporation has two new products that are Oxyglobin and Hemopure. Oxyglobin is the first new blood substitute for the veterinary market and is ready for consumer use. Hemopure is another new blood substitute for the human market and it will take two years to launch the product from now on. Ted Jacobs‚ vice president for Human Clinical
Premium Marketing Blood transfusion Blood
Q1. Should Biopure launch Oxyglobin? Why? Support your arguments with quantitative analysis (ie. calc. of market potential). We believe that Biopure should launch Oxyglobin now. First of all‚ the potential market demand is huge. While current annual demand is 354‚750 units (95% primary care practices x 17 units canine blood/primary care practice + 5% specialty care practices x 150 units canine blood/specialty care practice)i accounting for only 2.5% of the cases‚ potential market demand including
Premium Blood Marketing Blood transfusion
recommendation that Biopure should immediately launch Oxyglobin. The reasons for this decision are as followed: Obtaining the Monopoly on blood substitutes - If Biopure waits to launch Oxyglobin they will miss a prime opportunity to control the blood substitute market‚ especially the animal market. As mentioned in the case‚ Biopure’s competitors have yet to launch their products. Furthermore‚ Baxter International and Northfield Laboratories do not have an animal substitute for Biopure to compete with1
Premium Blood transfusion Blood Marketing
I. Identify/Define the Key Issues/Situation Analysis A. Key issues Although India has a huge blind population with cataract‚ few of them have access to surgery due to a lack of enough qualified ophthalmologists. On the strength of this‚ Dr. Venkataswamy established the successful Aravind Eye Hospital‚ and in turn wants to spread the Aravind model to every corner of India‚ other parts of Asia and Africa through franchising. To implement this model‚ Dr. V has to find solutions to the various problems
Premium Franchising Joint venture Knowledge
Please read "Children’s Hospital and Clinics (A)" available in the course packet and consider the following questions: 1) What is your assessment of the Patient Safety Initiative at Children’s? What do you think about blameless reporting? Answer: blameless reporting：Blameless reporting encouraged front line workers to use patient safety reports to discover and eliminate breakdowns in hospital systems and processes. Language 好处：Indeed‚ Morath emphasized the avoidance of several words that were indicative
Premium Patient safety Hospital accreditation Patient
(upward and downward communication problem) The safety memo case proved that The Cable Company has problems with communication between managers and employees at every level of hierarchy at the company. There is not a clear direction given for what job duties are performed by whom. If important information is needed to be given‚ there is no set protocol on how to do so or who to report to. There is no chain of command identifiable and thus creates confusion on how processes should be done
Premium Communication Nonviolent Communication Employment
Memorandum Re: Case Memo of The Wm.Wrigley.Jr.Company In the case Blanka Dobynin was are trying to buy a large stake in the company and thereby force the management to reorganize the capital structure by raising the debt and using it to pay the dividends or buy back the shares. The strategy will benefit from the price appreciation from stock repurchase or dividend payment. Wrigley is a leading producer and distributor of chewing gums‚ and it has a advantageous position compared to the
Premium Stock market Finance